Testosterone Label Changes Could Make Advertising More Challenging
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA proposal obtained by “The Pink Sheet” DAILY eliminates language describing symptoms of low testosterone.
You may also be interested in...
Another Testosterone Warning – This Time For Abuse
Action follows agency review of 81 adverse events reported with testosterone/anabolic androgenic steroid misuse, abuse, or dependence over 45 years; discussions continue on cardiovascular study.
Disease-Awareness Ads Thrive In Regulatory No-Man’s Land
FDA says its hands are tied when it comes to curbing practices such as the testosterone ads its advisory committees have found problematic, but are the agency’s powers really that limited?
The Next Estrogen Or An Off-Label Star: Can FDA Turn Back The Clock On Testosterone?
Testosterone replacement products took a hit after an FDA advisory committee, but even if the agency follows their advice, panelists worried a label change will not curb use in the now infamous “Low-T” population; meanwhile, a vigorous pipeline of new testosterone formulations may be left in limbo.